Clinical research organizations
Clinical research organizations run drug, device and vaccine trials for sponsors: recruiting volunteers and patients, dosing them in their own units or at partner sites, monitoring safety and managing trial data. The exposure is people given unproven treatments, sponsor contracts that shift liability, and a large store of sensitive health data.
Where losses come from.
- 01
Volunteers and patients harmed by investigational drugs, devices or dosing errors during a trial
- 02
Consent, eligibility or protocol failures that injure subjects or void a sponsor's data
- 03
Breaches and outages of trial databases holding health records and unblinded results
- PropertyProperty: Elevated, 3 of 5; sector average 1.6; all business types 2.9.
- Business interruptionBusiness interruption: Elevated, 3 of 5; sector average 2.0; all business types 2.7.
- Premises liabilityPremises liability: Elevated, 3 of 5; sector average 2.2; all business types 2.7.
- Products and completed workProducts and completed work: Elevated, 3 of 5; sector average 1.7; all business types 2.6.
- Workers’ injuryWorkers’ injury: Moderate, 2 of 5; sector average 2.0; all business types 3.0.
- Commercial autoCommercial auto: Moderate, 2 of 5; sector average 2.1; all business types 2.5.
- Crime and theftCrime and theft: Elevated, 3 of 5; sector average 2.1; all business types 2.2.
- Inland marine and equipmentInland marine and equipment: Elevated, 3 of 5; sector average 2.4; all business types 2.6.
- EnvironmentalEnvironmental: Moderate, 2 of 5; sector average 1.5; all business types 2.3.
- Cyber and dataCyber and data: High, 4 of 5; sector average 3.1; all business types 2.7.
- Professional liabilityProfessional liability: Severe, 5 of 5; sector average 3.4; all business types 2.0.
- Umbrella and excessUmbrella and excess: High, 4 of 5; sector average 2.8; all business types 3.6.
- Decentralized trials send nurses, devices and study drug to subjects' homes, adding driving, home-visit and courier exposure while shrinking time in the clinic.
- Wearables, apps and remote consent collect more subject data from more places, widening breach and privacy exposure across regions with differing rules.
- Cell, gene and other advanced therapies push more first-in-human and high-risk dosing into CRO units, raising the severity of a single adverse event.
Twelve lines, rated.
Each line shows its rating and the reason for it; open a line for what to watch for and the controls that matter. Ratings are UrbanStat’s own editorial view of a typical business of this type, on a five-step scale. They are a starting point for questions, not a quote, a rate or a statistical measure.
Property
ElevatedOffices carry little hazard, but clinical units, bioanalytical labs and sample freezers hold costly, irreplaceable material sensitive to smoke, water and power loss.
Fire, explosion, water and weather damage to buildings, contents and stock.
- Ultra-low freezers holding trial samples with no alarm or backup unit
- Labs using solvents, dry ice and compressed gases beside clinical areas
- Study drug kept in one pharmacy room with no temperature backup
- Freezer alarms monitored around the clock with spare capacity on standby
- Standby generator covering freezers, drug refrigerators and data rooms
- Labs separated from clinical and office areas by fire-rated walls
Business interruption
ElevatedA lost clinical unit or sample store halts enrolled studies, and sponsors move work elsewhere rather than wait for a rebuild.
How long and how costly a shutdown is.
- One clinical pharmacology unit earning most of the revenue
- Milestone-based contracts where payment stops when a study pauses
- Agreements with partner sites to take over enrolled studies
- Duplicate sample sets split between two storage locations
Premises liability
ElevatedHealthy volunteers live in phase I units for days, and patients visit for dosing and blood draws, then faint, fall or need emergency transfer.
Injuries to customers and the public, on site or caused by operations elsewhere.
- Overnight units with shared rooms, showers and recreation areas
- Paid volunteers who conceal health conditions or drug use
- Volunteers and visitors moving through buildings shared with labs
- Fall-risk checks and bed alarms in the hours after dosing
- Escorted access and supervised common areas in residential units
Products and completed work
ElevatedSubjects harmed by a sponsor's investigational product sue everyone in the chain, and CROs that pack, label or ship trial supplies share the blame.
Harm caused by what the business sells, serves, makes, installs or repairs.
- Clinical supply packaging, blinding and labeling done in house
- Sponsor indemnities that are missing, capped or from thinly funded start-ups
- Written sponsor indemnity and proof of the sponsor's trial insurance
- Second-person checks on kit labels, randomization codes and expiry dates
Workers’ injury
ModerateMost staff are monitors, data managers and statisticians; clinic and lab staff face needlesticks, potent compounds, dry ice and lifting.
Injuries and illness to employees.
- Monitors traveling constantly between sites, often by long drives
- Clinic staff handling potent or cytotoxic investigational products
- Safety-engineered needles and sharps disposal at every draw station
- Closed handling and protective gear for potent compounds
Commercial auto
ModerateMonitors drive rented and personal cars to trial sites, and some units shuttle volunteers or send nurses on home visits.
Owned, hired and employee-driven vehicles, deliveries, customers’ vehicles in care.
- Volunteer shuttles or home-visit nursing in company vehicles
- Samples carried by staff rather than specialist couriers
- Hired and non-owned auto cover with driving record checks
- Specialist couriers for samples and investigational product
Crime and theft
ElevatedLarge pass-through payments to investigator sites, volunteer stipends and controlled study drugs invite payment fraud, fictitious subjects and diversion.
Burglary, robbery, employee dishonesty, cash, payment and invoice fraud.
- Changes to site payment details requested by email
- Controlled substances under study with weak dispensing records
- Volunteer stipends loaded onto prepaid cards by unsupervised staff
- Callback checks on every change of site or vendor bank details
- Double-locked drug storage with dispensing reconciled to dosing records
Inland marine and equipment
ElevatedStudy drug, temperature-controlled samples and loaned equipment move constantly between sponsors, sites, labs and depots.
Property in transit, at job sites or in the insured’s care, and mobile equipment.
- Samples shipped across borders on dry ice or liquid nitrogen
- Sponsor-owned drug and devices held with unclear custody terms
- Temperature loggers on every shipment with excursion procedures
- Contracts stating who bears loss of sponsor property in the CRO's care
Environmental
ModerateMedical waste, sharps, lab solvents and returned study drug need licensed disposal; radiolabeled studies add a small radioactive stream.
Pollution on or from the site or the work.
- Unused study drug returned from sites and stored awaiting destruction
- Radiolabeled or cytotoxic compounds used in clinic or lab
- Licensed medical and chemical waste contractors issuing destruction certificates
Cyber and data
HighTrial data systems and safety databases hold patients' health records and sponsors' unblinded results, and an outage stops trials in many regions.
Data breaches, ransomware, system outages and attacks on connected equipment.
- Trial systems open to many outside sites, sponsors and vendors
- Older validated systems left unpatched to avoid revalidation
- Subjects' health records held across regions with differing privacy rules
- Multi-factor access and prompt removal of departed site users
- Tested restores of trial databases from offline backups
- Patching and revalidation plan agreed with sponsors in advance
Professional liability
SevereDosing errors, missed safety signals, consent failures and data errors can injure subjects or cost a sponsor its approval timeline.
Loss or injury caused by advice, design, testing, care or another professional service.
- First-in-human and high-risk dosing studies in the CRO's own unit
- Sponsor contracts making the CRO liable for delays or rejected data
- Investigators and nurses whose licenses and training go unverified
- Independent safety review and staggered dosing in early-phase studies
- Liability caps tied to fees, with sponsor indemnity for product harm
- Audit trails, quality reviews and deviation tracking on every study
Umbrella and excess
HighA severe reaction in a first-in-human cohort can leave several healthy volunteers critically injured at once, far beyond primary limits.
How likely one liability event is to exhaust primary limits.
- Early-phase units dosing several volunteers on the same day
- Sponsors with thin balance sheets and low trial insurance limits
- Sentinel dosing with a waiting period before the rest of the cohort
- Proof of adequate sponsor limits before each study starts
Construction, occupancy, protection, exposure.
What a risk engineer expects to find at a typical site of this type, and what to compare a submission against.
- Construction
- Modern office buildings or business-park units, often with a fitted-out clinical unit, bioanalytical lab and sample store in the same building as offices.
- Occupancy
- Clinical wards with beds, medical gases and pharmacy rooms; labs with solvents, dry ice and liquid nitrogen; banks of ultra-low freezers running around the clock.
- Protection
- Full sprinklers, labs in separate fire areas, monitored freezer and temperature alarms, a standby generator for clinical and cold storage, and controlled access to dosing areas.
- Exposure
- Units often sit near hospitals or in mixed business parks; a neighbor's fire or a utility outage threatens freezers and dosed volunteers who cannot simply leave.
What to ask and look for.
Start with the desk review before quoting, then walk the site. Tick questions off as you go; ticks are kept in this browser only.
Before quoting: ask the broker or owner
Documents to request
On site: clinical unit
On site: pharmacy, labs and samples
On site: data and systems
On site: people and quality
Refer or decline if you find
- First-in-human studies with no sentinel dosing or on-site emergency cover
- Sponsor contracts with no indemnity for injuries caused by the product
- Freezers holding trial samples with no remote alarm or backup power
- Repeated inspection findings on consent, eligibility or data integrity
- Subjects enrolled at sites whose investigators were never vetted
How UrbanStat data helps.
Sample freezers, drug refrigerators and dosed volunteers depend on steady power. Floods, hurricanes and earthquakes that cut utilities for days threaten irreplaceable samples and force evacuation of residential units.
- Flood and hurricane scores at the address show whether freezer rooms and drug stores on lower floors are exposed, before pricing spoilage and interruption cover.
- Live event overlays during a hurricane or wildfire show which clinical units and sample stores sit in the path, while there is still time to move samples.
- Street-by-street exposure views show insured values clustering where several labs and clinical units share a research park, with alerts when a set threshold is passed.
What the published numbers say.
Official statistics for the industry or property type closest to this business. They describe the industry as a whole, not any one insured.
0.6 recordable injuries and illnesses per 100 full-time workers, below the private-industry average of 2.3.
0.1 of these cases per 100 workers involved days away from work.
United States, 2024. Industry: Scientific research and development services (NAICS 5417), the closest published group. Source: U.S. Bureau of Labor Statistics, Survey of Occupational Injuries and Illnesses, Table 1: incidence rates of nonfatal occupational injuries and illnesses by industry and case types, 2024.
65 fatal work injuries in 2024, most often from transportation incidents (23).
United States, private industry, 2024. Industry: Professional, Scientific, and Technical Services (NAICS 541), the closest published group. Source: U.S. Bureau of Labor Statistics, Census of Fatal Occupational Injuries.
34 citations from 13 inspections; 74% were classed serious, willful or repeat.
- 1910.147 The control of hazardous energy (lockout/tagout)5
- 1910.1450 Occupational exposure to hazardous chemicals in laboratories4
- 1910.212 General requirements for all machines2
- 1910.141 Sanitation2
- 1910.157 Portable fire extinguishers2
Standards cited most often in this industry, by number of citations.
United States, citations issued October 2024 to September 2025 (federal fiscal year 2025). Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (NAICS 541715). Covers federal and state-plan inspections. A citation is one violation item; one inspection can produce several. Source: U.S. Department of Labor, Occupational Safety and Health Administration, OSHA enforcement data (inspections and violations); standard titles from the Code of Federal Regulations, Title 29 (section headings).
5,750 fires a year reported in health care properties, causing about $50 million in direct property damage a year.
- Cooking equipment66%
- Electrical distribution and lighting equipment6%
- Intentional6%
- Heating equipment5%
Leading causes, share of fires.
United States, 2011 to 2015, annual average. Nursing homes, hospitals, mental health facilities and clinics. Source: National Fire Protection Association, Structure Fires in Health Care Facilities.
13 facilities reported toxic chemical releases totaling 506,672 pounds on and off site.
- Lead238,325
- Chromium105,647
- Nitrate compounds88,041
Chemicals released in the largest amounts, in pounds. 8 of the facilities reported at least one chemical classed as a carcinogen.
United States, 2024. Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (NAICS 541715). Covers facilities in listed industries with ten or more full-time employees that handle listed chemicals above set thresholds. Source: U.S. Environmental Protection Agency, Toxics Release Inventory basic data files.
Industry loss ratios by line2020 to 2024, the same table on every guide
Loss ratios are published by line of insurance, not by business type. They show how each line has run for insurers as a whole, whatever the business insured.
| Published line | Closest line in this guide | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Fire | Property | 63.2% | 67.3% | 62.4% | 45.5% | 40.9% |
| Commercial multiple peril | Property and liability sold as a package | 61.2% | 60.2% | 59.4% | 61.2% | 54.4% |
| Inland marine | Inland marine and equipment | 64.5% | 49.4% | 47.1% | 44.1% | 44.0% |
| Other liability | Premises liability, and most umbrella, professional (other than medical) and cyber cover | 65.1% | 58.8% | 61.0% | 63.7% | 71.2% |
| Products liability | Products and completed work | 48.2% | 52.2% | 46.0% | 57.5% | 60.3% |
| Workers’ compensation | Workers’ injury | 47.9% | 49.2% | 45.0% | 44.3% | 46.0% |
| Commercial auto liability | Commercial auto | 68.3% | 66.5% | 71.9% | 76.8% | 77.6% |
| Commercial auto physical damage | Commercial auto | 50.9% | 56.3% | 64.3% | 65.1% | 57.9% |
United States. Losses incurred as a percent of direct premiums earned, countrywide, before reinsurance and not including loss adjustment expense. Source: National Association of Insurance Commissioners, Report on Profitability by Line by State in 2024, ten-year summary.
- Clinical trials liability
- Subjects injured by an investigational product need cover that responds without proving fault, and many regions require it.
- Abuse and molestation
- Residential phase I units, pediatric studies and sedated or cognitively impaired patients put staff alone with vulnerable subjects.
- Equipment breakdown
- Freezer compressors, generators and analyzers fail without any fire, and the samples inside cannot be collected again.
- Spoilage of samples and study drug
- A long power outage or freezer failure destroys samples and sponsor drug held at controlled temperatures.
- Directors and officers
- Failed trials, data integrity findings and sponsor disputes bring claims against management, especially at investor-backed or listed firms.
| System | Code | Industry |
|---|---|---|
| NAICS 2022, primary | 541715 | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| NAICS 2022 | 541714 | Research and Development in Biotechnology (except Nanobiotechnology) |
| SIC 1987, primary | 8731 | Commercial Physical and Biological Research |
See this risk on the map.
Book a 30-minute walkthrough tailored to your portfolio and perils of interest.